Form 4: Tonix Pharmaceuticals' Chief Medical Officer Granted Stock Options

Gregory M. Sullivan, Chief Medical Officer of Tonix Pharmaceuticals, was granted stock options on February 27, 2024.

Summary

• Gregory M. Sullivan, the Chief Medical Officer of Tonix Pharmaceuticals Holding Corp., was granted stock options on February 27, 2024.
• The options are for 358,000 shares at an exercise price of $0.368 and another 358,000 shares at an exercise price of $0.46.
• The options vest in installments starting February 27, 2025, and expire on February 27, 2034.
• The options were granted under the company's Amended and Restated 2020 Stock Incentive Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard executive compensation event. The grant of options can be seen as a positive sign of confidence in the executive and the company's future, but it also represents potential dilution for existing shareholders.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• The vesting schedule of one-third on the first anniversary and 1/36th each month thereafter for 24 months is a typical vesting structure.
• Exercise prices are generally set at or above the market price of the stock on the grant date.

Stakeholder Impact

• Shareholders may experience potential dilution if the options are exercised.
• Employees may view the option grant as a positive sign of the company's commitment to its executives.

Key Dates